Table 3.
Summary of clinical assays of drugs targeting cell metabolism.
| Publication Date | Type of Study * | Virus/Disease | Type of Infection (Time to Treatment Interval) † | Drug | Target | Pharmaceutical Form | Patient Age | Ref. |
|---|---|---|---|---|---|---|---|---|
| January 1987 | Rdm DB PC phase II | RV-A39 | Inoculation (−1 day) | Atropine Methonitrate | Anticholinergic | Nasal spray | >18 years old | [69] |
| 23 July 2020 | Rdm DB PC phase III | EV, RV | Inoculation | CUR-N399 | PI4KIII β | Oral capsule | >18 years old | [70] |
| September 2010 | Rdm DB PC phase II | RV-A39 | Inoculation (−3 h) | Oxymetazoline | α-Adrenoreceptor | Intranasal liquid | 18–65 years old | [71] |
* Rdm = randomized; DB = double–blind; PC = placebo-controlled. † Negative delay means that the treatment began before the virus challenge or symptoms onset.